The trajectory of the erectile dysfunction drug presents a intricate picture for investors. While the initial launch generated substantial gains, the lapse of its patent opened the door to cheaper competitors, https://bookmarkport.com/story24468251/the-copyright-and-the-pharmaceutical-industry-a-precarious-opportunity